Dupixent, 1st biologic approved for pruritic rash indication
By Son, Hyung-Min | translator Kim, Jung-Ju
24.02.28 12:05:36
가나다라
0
This marks the third indication for Dupixent, following its approval for treating ‘atopic dermatitis and asthma’
Dupixent demonstrated efficacy in the PRIME clinical study, showing improvement in the Worst-Itch Numeric Rating Scale (WI-NRS)
▲Professor Ahn Ji Young, affiliated with the Department of Dermatology at the National Medical Center.
As Dupixent is approved to treat prurigo nodularis (nodular itchy rash), the drug emerged as the only available treatment option among biologic agents. Previously, there were limited treatment options for treating prurigo nodularis, a condition that causes extreme itchiness.
Sanofi hosted a press conference at Novotel Ambassador Seoul Gangnam on the 28th to commemorate the company’s expansion of Dupixent indications to treat prurigo nodularis.
Dupixent is a biological agent designed to target interleukin (IL)-4 and IL-13 signaling pathway, biomarkers of type 2 inflammation, and regulates the symptoms. The drug has shown effects in inflammatory diseases such as atopic dermatiti
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)